PCN194 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.390
https://www.valueinhealthjournal.com/article/S1098-3015(19)32768-8/fulltext
Title :
PCN194 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32768-8&doi=10.1016/j.jval.2019.09.390
First page :
Section Title :
Open access? :
No
Section Order :
10322